Bone defect diseases, particularly induced by inflammation, render a challenge for designing ideal drug-loading scaffold that could facilitate bone repairing and eliminate inflammatory pathogens. LL37 is considered as promising alternative loading drug due to its broad-spectrum antimicrobial effect and various bio-functions including osteogenic induction. In this study, we synthesized modified LL37 by adding collagen binding domain (CBD), which aim to provide a specific binding onto collagen and slow-releasing pattern. The modified peptide was proved to exhibit similar biological activities to nature LL37 on rat BMSCs including promoting migration activity, anti-inflammatory activity and osteogenic induction in vitro. Ectopic bone formation experiment further confirmed the angiogenesis and osteoinduction activities in vivo. Collectively, LL37-CBD may be a potential loaded drug for preventative and curative applications in Inflammation-induced bone diseases, exerting dual strategies including anti-inflammatory and osteogenic effects.